Alfacell (ACEL): A cure for Mesothelioma

Normally we don't write about penny stocks here at the Stockmasters. But Alfacell Corporation (Public, OTC:ACEL) caught my eye as a potential low risk/high reward play.

Could Alfacell be the next big name moving the markets in the Pharma Sector?

Alfacell Corporation is currently conducting a centrally randomized, international, confirmatory Phase IIIb clinical trial of its lead investigational drug, ONCONASE (ranpirnase) for patients with Malignant Mesothelioma.

ONCONASE (ranpirnase) is a single peptide chain containing 104 amino acids. Ranpirnase has a molecular mass of approximately 12,000 daltons and an isoelectric point of approximately 9.5. The amino terminal residue is pyroglutamate.

In cancer cells, ONCONASE-induced intracellular RNA degradation triggers several biological effects simultaneously including the induction of the "intrinsic" (mitochondria) pathway of apoptosis and modulation of the expression of several key cell cycle regulatory factors

Fellow Masters, if Alfacell passes the Phase III trials for ONCONASE and gets FDA approval to treat Mesothelioma, the stock will soar. Think of Dendreon's (DNDN) huge jump earlier this year.

However, there is a lot of risk associated with the stock. If the drug fails to get FDA approval, you can kiss your investment goodbye.

ACEL 1 Year Chart